The Allergan Integration Playbook — Diversification by Design

In May 2020, AbbVie completed a $63 billion acquisition of Allergan — one of the largest pharma deals in history — transforming itself from an immunology-heavy company into a diversified biopharma spanning aesthetics, eye care, women's health, and neuroscience. This module explains the deal's strategic logic, the integration playbook AbbVie used, and what candidates can learn from it about how the company values cross-functional execution.